Renhaim Inc.
is strategically advancing the development of
state-of-the-art biopharmaceuticals
Renhaim Inc. is proactively creating a BIO ECO SYSTEM by leveraging
RNA-based drug development and fostering robust partnerships with leading collaborators,
all driven by open innovation, to pioneer advanced biopharmaceutical solutions.
Mission
Shareholder value system
The goal of raising the value of shareholders
by generating profits through
new drugs' development
and maximizing corporate value
Development of
Genetic-Based New Drugs
Development of genome-based
new drug formulations including RNA through
commercialization using advanced
genome technology and open innovation
Fulfilling Social
Responsibility through
Innovative Drug Development
We are working on the development of
anti-cancer agents and gene cell therapies
addressing unmet medical needs.
ESG management
Pursuing sustainable management
by reconsidering responsibility
for the environment and society and
transparency of governance structure
Shareholder value system
The goal of raising the value of shareholders
by generating profits through
new drugs' development
and maximizing corporate value
Development of
Genetic-Based New Drugs
Development of genome-based
new drug formulations including RNA through
commercialization using advanced
genome technology and open innovation
New drug development fulfills social responsibility
Development of anti-cancer drugs,
premium prevention vaccines,
and fundamental disease treatments
with Medical Unmet Needs
ESG management
Pursuing sustainable management
by reconsidering responsibility
for the environment and society and
transparency of governance structure
Vision
